Division of Alphaeon Corp.
Latest From Evolus Inc.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
A claim that RT002's duration of efficacy surpasses the leading neurotoxin – Allergan's blockbuster Botox – will be put to the test when Revance seeks US FDA approval to treat frown lines in the first half of this year. The company's Botox biosimilar with Mylan also could move forward in 2019.
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Alphaeon Corp.
- Senior Management
David Moatazedi, Pres. & CEO
Lauren Silvernail, CFO & EVP, Corp. Dev.
J. Christopher Marmo, PhD, COO
Rui Avelar, MD, Head, R&D & CMO
Michael Mazen Jafar, Chief Mktg. Officer
- Contact Info
Phone: (949) 284-4555
520 Newport Center Dr.
Newport Beach, CA 92660
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.